Drug intelligence / Profile preview

Ice lotus grass

Development stage: Unknown
Lead developer: Guizhou Bailing Group Pharmaceutical
Modality: Small Molecules
Administration: Buccal

Overview

"Ice lotus grass" is a drug formulated as buccal tablets, currently undergoing Phase II clinical trials for the treatment of mild recurrent aphthae ulcer, specifically addressing the Traditional Chinese Medicine (TCM) syndrome of accumulation of heat in the stomach and intestine. Developed by Guizhou Bailing Group Pharmaceutical Limited by Share Ltd, this preparation is believed to exert its therapeutic effects through mechanisms associated with clearing internal heat and reducing inflammation, likely involving various active compounds derived from herbal extracts.

Other names: 冰莲草含片

Targets

TRPC (TRPC family)TLR4 (Toll-like receptor 4)DRD1 (Dopamine D1 Receptor)Inwardly rectifying potassium channelNF-κBDRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on Ice lotus grass.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ice lotus grass.

Explore the full profile